Article thumbnail

Lyprinol—Is It a Useful Anti-Inflammatory Agent?

By Sheila A. Doggrell

Abstract

The New Zealand green lipped mussel preparation Lyprinol is available without a prescription from a supermarket, pharmacy or Web. The Food and Drug Administration have recently warned Lyprinol USA about their extravagant anti-inflammatory claims for Lyprinol appearing on the web. These claims are put to thorough review. Lyprinol does have anti-inflammatory mechanisms, and has anti-inflammatory effects in some animal models of inflammation. Lyprinol may have benefits in dogs with arthritis. There are design problems with the clinical trials of Lyprinol in humans as an anti-inflammatory agent in osteoarthritis and rheumatoid arthritis, making it difficult to give a definite answer to how effective Lyprinol is in these conditions, but any benefit is small. Lyprinol also has a small benefit in atopic allergy. As anti-inflammatory agents, there is little to choose between Lyprinol and fish oil. No adverse effects have been reported with Lyprinol. Thus, although it is difficult to conclude whether Lyprinol does much good, it can be concluded that Lyprinol probably does no major harm

Topics: Review Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3163099
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2006). A meta-analysis of the analgesic effectsofomega-3polyunsaturatedfattyacidsupplementation for inflammatory joint pain,”
  2. (2004). Anti-TNF-α therapy for chronic inflammation: reconsidering pentoxifylline as an alternative to therapeutic protein drugs,”
  3. (2007). Anticyclooxygenase effects of lipid extracts from the New Zealand green-lipped mussel,
  4. (2008). Autologous interleukin-1 receptor antagonist improves function and symptoms in osteoarthritis when compared to placebo in a prospective randomized controlled trial,” Osteoarthritis and Cartilage,
  5. Available at http://www.lyprinol.com.
  6. (2002). B.Dobenecker,Y.Beetz,andE0Kienzle,“Aplacebo-controlled double-blind study on the effect of nutraceuticals (chondroitinsulphateandmusselextract)indogswithjointdiseases asperceivedbytheirowners,”JournalofNutrition,vol.132,pp. 1690S–1691S,
  7. Claims of media manipulation after NZ diet food frenzy,
  8. (2003). Clinical efficacy and safety of Lyprinol, a patented extract from New Zealand green-lipped mussel (Perna Canaliculus) in patients with osteoarthritis of the hip and knee: a multicenter 2-month clinical trial,”
  9. (2006). Clinical efficacy and tolerance of an extract of green-lipped mussel (Perna canaliculus) in dogs presumptively diagnosed with degenerative joint disease,”
  10. (2003). Combination antiinflammatory therapy: synergism in rats of NSAIDs/corticosteroidswith someherbal/animal products,”
  11. (1997). D.R.Haynes,andJ.Broadbent,“Anti-inflammatoryactivityof a lipid fraction (Lyprinol) from the NZ green-lipped mussel,”
  12. (2008). Differential protein expression induced by a lipid extract of Pernacanaliculusinsplenocytesofratswithadjuvant-inducedEvidence-Based
  13. (2004). Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee,”
  14. (2004). Efficacy and tolerability of a combination of Lyprinol and high concentrations of EPA
  15. (2009). Evaluating complementary therapies for canine osteoarthritispartI:green-lippedmussel(Pernacanaliculus),”
  16. Fish oil for induction of remission in ulcerative colitis,” Cochrane DatabaseofSystematicReviews,vol.4,articleCD005986,2007.
  17. (2004). Halpern GM: treatment of knee osteoporosis with Lyprinol, lipid extract of the green-lipped mussel – a double-blind placebo-controlled study,”
  18. (2006). In vitro modulation of inflammatory cytokine and IgG levels by extracts of Perna canaliculus,”
  19. (2001). Influence of green-lipped mussel (Perna canaliculus) in alleviating signs of arthritis is dogs,”
  20. (2008). Introductory information about Lyprinol,
  21. (1986). Isolation of ananti-histaminicsubstancefromgreen-lippedmussel(Perna canaliculus),”
  22. (2007). Karpaˇ s et al., “The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee,”ArthritisandRheumatism,vol.56,pp.4055–4064,
  23. (2007). L a w s o n ,S .M .B e l k o w s k i ,J .F .W h i t e s i d e s ,P .D a v i s ,a n dJ . W.Lawson,“Immunomodulationofmurinecollagen-induced arthritis by N, N-dimethylglycine and a preparation of Perna canaliculus,”
  24. (2002). Lipid, FA, and sterol composition of New Zealand green lipped mussel (Perna canaliculus) and Tasmanian blue mussel (Mytilus edulis),” Lipids,
  25. (2000). Lyprinol: antiinflammatory and uterine-relaxant activities in rats, with special reference to a model for dysmenorrhoea,”
  26. (2008). Mobicosa capsules—a natural arthritis treatment,
  27. (2006). n-3 polyunsaturated fatty acids, inflammation and inflammatory disease,”
  28. (2008). Omega-3 free fatty acids for the maintenance of remission in Crohn disease; the EPIC randomized controlled trial,”
  29. (2009). Pain controlling and Cytokine-regulating effects of lyprinol, a lipid extract of perna canaliculus, in a rat Adjuvant-induced arthritis model,” Evidence-Based Complementary and Alternative Medicine,
  30. (2000). Super-critical lipid extract from mussels having anti-inflammatory activity,”
  31. (2008). T o r r e s ,K .L .T o o l e y ,R .N .B u t l e r
  32. (2008). The CO2-SFE crude lipid extract and the free fatty acid extract from Perna canaliculus have anti-inflammatory effects on adjuvantinduced arthritis
  33. (1998). The treatment of arthritis with a lipid extract of Perna canaliculus: a randomized trial,”
  34. (2002). Treatment of asthma with lipid extract of New Zealand green-lipped mussel: a randomised clinical trial,”
  35. (2005). u r p h y ,M .L e ,P .R .H o w e ,a n dG .S . Howarth, “Lyprinol (stabilised lipid extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease,”